VCAM1 KO cell lysate available now. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 2.
Images
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Immunocytochemistry, Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 2
Alternative names
CD106, CD106 Antigen, INCAM-100, MGC99561, VCAM1_HUMAN, Vascular Cell Adhesion Molecule 1, Vascular cell adhesion protein 1
What's included?
Recommended products
VCAM1 KO cell lysate available now. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 2.
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Knockout validation
- Immunocytochemistry, Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 2
- Disease
- Carcinoma
- Concentration
Properties
- Gene name
- VCAM1
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Immunocytochemistry, Sanger Sequencing, Western blot
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Male
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Treatments:
Human VCAM1 knockout A549 cell lysate - Untreated
Human wild-type A549 cell lysate - Untreated
Human VCAM1 knockout A549 cell lysate - TNF-a (10 ng/ml, 16h)
Human wild-type A549 cell lysate - TNF-a (10 ng/ml, 16h)
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VCAM1 also known as vascular cell adhesion molecule 1 plays an important role in mediating adhesion and signal transduction. VCAM1 has an approximate molecular mass of 110 kDa. It is expressed on the surface of endothelial cells and can be upregulated by cytokines released during inflammation. The protein serves as a ligand for the integrin VLA-4 also known as α4β1 and contributes to the adhesion of leukocytes to endothelial cells.
- Biological function summary
Adhesion molecules like VCAM1 participate in immune response by recruiting leukocytes to sites of inflammation. VCAM1 helps guide immune cells to directed locations where they perform defense activities. Although VCAM1 is not part of any known large protein complex its interaction with integrins facilitates the migration of immune cells across the endothelium and into tissue.
- Pathways
VCAM1 contributes significantly to the leukocyte extravasation process in inflammatory pathways. It plays a role in both the cytokine-cytokine receptor interaction pathway and the NF-kB signaling pathway which are essential for immune response and cell signaling. Through these pathways it interacts with proteins like ICAM1 and various chemokines helping to coordinate the immune cell movement through vascular tissue barriers.
- Associated diseases and disorders
Abnormal regulation of VCAM1 links to various cardiovascular diseases such as atherosclerosis and inflammatory diseases like rheumatoid arthritis. The protein levels may increase in these conditions promoting excessive immune cell recruitment and tissue damage. VCAM1 also interfaces with other proteins like ICAM1 in these pathological states which together contribute to the progression and severity of these diseases.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human VCAM1 knockout A549 cell lysate (ab275504)
Lane 1: Wild-type A549 cell lysate 30 ug
Lane 2: Wild-type A549 TNF-a treated (10 ng/mL, 16h) cell lysate 30 ug
Lane 3: VCAM1 knockout A549 cell lysate 30 ug
Lane 4: VCAM1 knockout A549 TNF-a treated (10 ng/mL, 16h) cell lysate 30 ug
Lane 5: HUVEC cell lysate 30 ug
Lane 6: HUVEC TNF-a treated (16 ng/mL, 16h) cell lysate 30 ug
Lanes 1 - 6:Merged signal (red and green). Green - Anti-VCAM1 antibody [EPR5047] ab134047 observed at 105 kDa. Red - loading control Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55kDa.
Anti-VCAM1 antibody [EPR5047] ab134047 was shown to react with VCAM1 in wild-type A549 cells in Western blot with loss of signal observed in VCAM1 knockout cell line Human VCAM1 knockout A549 cell line ab273758 (knockout cell lysate ab275504). Wild-type A549 and VCAM1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with Anti-VCAM1 antibody [EPR5047] ab134047 and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 2000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.All lanes: Western blot - Anti-VCAM1 antibody [EPR5047] (Anti-VCAM1 antibody [EPR5047] ab134047) at 1/2000 dilution
Lane 1: Wild-type A549 cell lysate at 30 µg
Lane 2: Wild-type A549 TNF-a treated (10 ng/mL, 16h) cell lysate at 30 µg
Lane 2: Western blot - Human VCAM1 knockout A549 cell line (Human VCAM1 knockout A549 cell line ab273758)
Lane 3: VCAM1 knockout A549 cell lysate at 30 µg
Lane 4: VCAM1 knockout A549 TNF-a treated (10 ng/mL, 16h) cell lysate at 30 µg
Lane 5: HUVEC cell lysate at 30 µg
Lane 6: HUVEC TNF-a treated (16 ng/mL, 16h) cell lysate at 30 µg
Performed under reducing conditions.
Predicted band size: 81 kDa
Observed band size: 105 kDa
Western blot - Human VCAM1 knockout A549 cell lysate (ab275504)
Lane 1: Wild-type A549 cell lysate 30 ug
Lane 2: Wild-type A549 TNF-a treated (10 ng/mL, 16h) cell lysate 30 ug
Lane 3: VCAM1 knockout A549 cell lysate 30 ug
Lane 4: VCAM1 knockout A549 TNF-a treated (10 ng/mL, 16h) cell lysate 30 ugLanes 1: Wild-type HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate, 20 ug
Lanes 2: GPX4 knockout HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate, 20 ug
Lanes 3: Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate, 20 ug
Lanes 3: Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate, 20 ugAnti-VCAM1 antibody [EPR5038(2)] ab174279 was shown to react with VCAM1 in treated wild-type A549 cells in western blot. Loss of signal was observed when treated VCAM1 knockout cell line Human VCAM1 knockout A549 cell line ab273758 (knockout cell lysate ab275504) was used. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with Anti-VCAM1 antibody [EPR5038(2)] ab174279 overnight at 4 °C at a 1 in 1000 dilution. Blots were incubated with HRP conjugated Goat anti-Rabbit (H+L) secondary antibody at 1 in 5000 for 1 hour at room temperature before development with Optiblot ECL reagent (Anti-PKC delta (phospho S299) antibody [EPNCI119] ab133456) and imaging.
All lanes: Western blot - Anti-VCAM1 antibody [EPR5038(2)] (Anti-VCAM1 antibody [EPR5038(2)] ab174279) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 30 µg
Lane 2: Wild-type A549 TNF-a treated (10 ng/mL, 16h) cell lysate at 30 µg
Lane 3: VCAM1 knockout A549 cell lysate at 30 µg
Lanes 3 - 4: Western blot - Human VCAM1 knockout A549 cell line (Human VCAM1 knockout A549 cell line ab273758)
Lane 4: VCAM1 knockout A549 TNF-a treated (10 ng/mL, 16h) cell lysate at 30 µg
Performed under reducing conditions.
Predicted band size: 81 kDa
Observed band size: 105 kDa
Exposure time: 20s
Sanger Sequencing - Human VCAM1 knockout A549 cell lysate (ab275504)
Allele-1: 4 bp deletion in exon 2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com